Clinical trials with new drugs
APEX
Patient target group
Study details
​
​
​
Name of study
​​
​
​
​
​
Sponsor
Clinical Center
​
​
​
​
​
​
​
HARBOR
Patient target group
Study details
​
​
​
​
Name of Study
​​
​
Sponsor
Clinical Center
​
​
​
​
​
​
​
​
​
PIONEER
Target of patients
​
Study details
​
​
​
Name of Study
​​
​
​
​
​
​
Sponsor
Clinical Center
​
​
​
​
​
​
​
​
​
​
​
SUMMIT
Target of patients
Study details
​
​
​
​
Name of Study​
​
​
​
Sponsor
Clinical Center
Patient target group
Advanced systemic mastocytosis
Study details
Study to test the efficacy and safety of the tyrosine kinase inhibitor bezuclastinib in patients with advanced systemic mastocytosis
Name of study
A Phase 2, Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (APEX)
Sponsor
Cogent
Clinical Center
University Hospital Basel, current status: Patients wanted (recruitement open)
​
​
Patient target group
Indolent sysstemic mastocytosis
Study details
Study to evaluate the efficacy and safety of the tyrosine kinase inhibitor elenestinib (compared to placebo) in patients with indolent systemic mastocytosis
Name of Study
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-26 in Indolent Systemic Mastocytosis (HARBOR)
Sponsor
Blueprint
Clinical Center
University Hospital Basel, current status: No new patients can be included in the study until 2024 (recruitment paused)
Luzerner Kantonsspital, current status: no patients can be included in the study until 2024 (recruitment paused)
​
​
​
​
Patient target group
Indolent and smoldering systemic mastocytosis
Study details
Study to test the efficacy and safety of the tyrosine kinase inhibitor avapritinib in patients with indolent systemic mastocytosis
Name of Study
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy (PIONEER)
Sponsor
Blueprint
Clinical Center
University Hospital Basel, current status: no more patients needed for the study (recruitment completed)
​
​
..
Patient target group
Indolent systemic mastocytosis
Name of Study
Study to test the efficacy and safety of the tyrosine kinase inhibitor bezuclastinib (compared to placebo) in patients with indolent systemic mastocytosis
Study details
A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with Nonadvanced Systemic Mastocytosis (SUMMIT)
Sponsor
Cogent
Clinical Center
University Hospital Basel, current status: Patients wanted (recruitment open)
Registries / Observational Studies
ECNM Registry
Patient target group
Study details
Name of study
Sponsor
Clinical Centers
Patient target group
All forms of mastocytosis
Study details
International registry for patients with mastocytosis
Name of Study
Data Registry of the European Competence Network on Mastocytosis (ECNM)
Sponsor
Prof. Dr. Wolfang Sperr and Prof. Dr. Peter Valent, Medical University of Vienna
Clinical Center
Kantonsspital Aarau, current status: patients wanted (recruitment open)
University Hospital Basel, current status: patients wanted (recruitment open)
Luzerner Kantonsspital, current status: patients wanted (recruitment open)
Biobank
Biobank Allergy and Immunity, University Hospital Basel
Patient target troup
Details
Sponsor
Status
Patient target group
All forms of mastocytosis
Study details
Collection of biological material (blood, tissue samples) of patients with mastocytosis to investigate basic disease mechanisms
Sponsor
Prof. Dr. Karin Hartmann, University Hospital Basel and University of Basel
Status
Patients wanted (recruitment open)